B Michael Silber, PhD

Title(s)Professor, Bioengineering
SchoolSchool of Pharmacy
AddressLocation Required
Varies CA 00000
Phone650-269-8044
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California San Francisco, Graduate SchoolPhD1981Pharmaceutical Chemistry and Pharmacology
    University of California San FranciscoPostdoctoral Fellowship1977Clinical Pharmacy
    University of Southern CaliforniaDoctor of Pharmacy1976Clinical Pharmacy

    Collapse Overview 
    Collapse Overview
    Dr. Silber is Professor, Department of Bioengineering and Therapeutic Sciences, University of California San Francisco (UCSF), Schools of Medicine and Pharmacy. Until recently, he was also Professor of Neurology and Chief of Drug Discovery R & D at UCSF’s Institute for Neurodegenerative Diseases, which he led. Current research interests include discovering, developing and launching innovative breakthrough therapeutic and diagnostic products for diseases with high unmet medical need, including pain, inflammation, cancer, eye, neurodegenerative, and infectious diseases.

    He is also President and CEO of Reiley Pharmaceuticals focused on breakthrough products for pain, cancer and infectious disease, President and CEO of MacRegen focused on breakthrough drugs for age-related macular degeneration, Senior Advisor at Clinakos, Novakos, and Neurokos, and Scientific Advisory Board member of NextBio/Illumina and Optivia. He was previously President and CEO of Elmedtech, Senior VP of R & D at Roche, VP of R & D and CSO at ALZA/J & J, Director of R & D at Pfizer, Senior Director of R & D at Cetus, and Director of R & D at Lederle Labs.

    Dr. Silber has contributed to the discovery, preclinical and clinical development, registration, or commercial success of 23 FDA approved drugs (12 of which have been block busters) and drug devices and diagnostics in many disease areas. He is the author of more than 215 peer-reviewed publications, book chapters, patents, abstracts, and invited presentations.

    He has discovered and developed medicines and breakthrough technologies in pain, neurological and neurodegenerative (e.g., Alzheimer’s, Parkinson’s, ALS, MS, FTD, TBI, CTE, CJD), psychotherapeutic (e.g., depression, schizophrenia, ADHD), cancer, eye disease, obesity, diabetes, infectious, lipid, inflammatory, cardiovascular, skin, and respiratory diseases.

    Hobbies include mentoring graduate and health profession students, tennis, skiing, photography, and travel.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice. J Pharmacol Exp Ther. 2016 09; 358(3):537-47. Giles K, Berry DB, Condello C, Dugger BN, Li Z, Oehler A, Bhardwaj S, Elepano M, Guan S, Silber BM, Olson SH, Prusiner SB. PMID: 27317802; PMCID: PMC4998675.
      View in: PubMed   Mentions: 11     Fields:    Translation:Animals
    2. Different 2-Aminothiazole Therapeutics Produce Distinct Patterns of Scrapie Prion Neuropathology in Mouse Brains. J Pharmacol Exp Ther. 2015 Oct; 355(1):2-12. Giles K, Berry DB, Condello C, Hawley RC, Gallardo-Godoy A, Bryant C, Oehler A, Elepano M, Bhardwaj S, Patel S, Silber BM, Guan S, DeArmond SJ, Renslo AR, Prusiner SB. PMID: 26224882; PMCID: PMC4576665.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    3. Novel compounds lowering the cellular isoform of the human prion protein in cultured human cells. Bioorg Med Chem. 2014 Mar 15; 22(6):1960-72. Silber BM, Gever JR, Rao S, Li Z, Renslo AR, Widjaja K, Wong C, Giles K, Freyman Y, Elepano M, Irwin JJ, Jacobson MP, Prusiner SB. PMID: 24530226; PMCID: PMC3984052.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    4. OMICS in Neuroscience, Giovanni Coppola Editor. From Small Molecule Leads to Clinical Candidates in Neurological Diseases. 2014; 291-314. . View Publication.
    5. Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. Bioorg Med Chem. 2013 Dec 15; 21(24):7999-8012. Silber BM, Gever JR, Li Z, Gallardo-Godoy A, Renslo AR, Widjaja K, Irwin JJ, Rao S, Jacobson MP, Ghaemmaghami S, Prusiner SB. PMID: 24183589; PMCID: PMC3984054.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    6. Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice. J Pharmacol Exp Ther. 2013 Nov; 347(2):325-38. Lu D, Giles K, Li Z, Rao S, Dolghih E, Gever JR, Geva M, Elepano ML, Oehler A, Bryant C, Renslo AR, Jacobson MP, Dearmond SJ, Silber BM, Prusiner SB. PMID: 23965382; PMCID: PMC3807058.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    7. Optimization of Arylamides as Novel, Potent and Brain-penetrant Antiprion Lead Compounds. ACS Med Chem Lett. 2013 Jul 11; 4(7):647-650. Li Z, Rao S, Gever JR, Widjaja K, Prusiner SB, Silber BM. PMID: 23977416; PMCID: PMC3746989.
      View in: PubMed   Mentions: 5  
    8. Discovery and Preliminary SAR of Arylpiperazines as Novel, Brainpenetrant Antiprion Compounds. ACS Med Chem Lett. 2013 Apr 11; 4(4):397-401. Li Z, Gever J, Rao S, Widjaja K, Prusiner SB, Silber BM. PMID: 23847718; PMCID: PMC3704178.
      View in: PubMed   Mentions: 4  
    9. 2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease. ChemMedChem. 2013 May; 8(5):847-57. Li Z, Silber BM, Rao S, Gever JR, Bryant C, Gallardo-Godoy A, Dolghih E, Widjaja K, Elepano M, Jacobson MP, Prusiner SB, Renslo AR. PMID: 23509039; PMCID: PMC3984044.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    10. Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice. Pharm Res. 2013 Apr; 30(4):932-50. Silber BM, Rao S, Fife KL, Gallardo-Godoy A, Renslo AR, Dalvie DK, Giles K, Freyman Y, Elepano M, Gever JR, Li Z, Jacobson MP, Huang Y, Benet LZ, Prusiner SB. PMID: 23417511; PMCID: PMC3640342.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    11. Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity. Eur J Med Chem. 2011 Sep; 46(9):4125-32. Thompson MJ, Louth JC, Ferrara S, Jackson MP, Sorrell FJ, Cochrane EJ, Gever J, Baxendale S, Silber BM, Roehl HH, Chen B. PMID: 21726921.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    12. 2-Aminothiazoles as therapeutic leads for prion diseases. J Med Chem. 2011 Feb 24; 54(4):1010-21. Gallardo-Godoy A, Gever J, Fife KL, Silber BM, Prusiner SB, Renslo AR. PMID: 21247166; PMCID: PMC3041857.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    13. Driving drug discovery: the fundamental role of academic labs. Sci Transl Med. 2010 May 05; 2(30):30cm16. Silber BM. PMID: 20445199.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    14. Toward a 21st-century health care system: recommendations for health care reform. Ann Intern Med. 2009 Apr 07; 150(7):493-5. Arrow K, Auerbach A, Bertko J, Brownlee S, Casalino LP, Cooper J, Crosson FJ, Enthoven A, Falcone E, Feldman RC, Fuchs VR, Garber AM, Gold MR, Goldman D, Hadfield GK, Hall MA, Horwitz RI, Hooven M, Jacobson PD, Jost TS, Kotlikoff LJ, Levin J, Levine S, Levy R, Linscott K, Luft HS, Mashal R, McFadden D, Mechanic D, Meltzer D, Newhouse JP, Noll RG, Pietzsch JB, Pizzo P, Reischauer RD, Rosenbaum S, Sage W, Schaeffer LD, Sheen E, Silber BM, Skinner J, Shortell SM, Thier SO, Tunis S, Wulsin L, Yock P, Nun GB, Bryan S, Luxenburg O, van de Ven WP. PMID: 19258550.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    15. Pharmacogenetics, Edited by Werner Kalow, Urs Meyer and Rachel Tyndale. Pharmacogenomics, Biomarkers and the Promise of Personalized Medicine. 2001; 11-31. .
    16. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci. 2000; 2(4):E33. McElroy S, Sachse C, Brockmoller J, Richmond J, Lira M, Friedman D, Roots I, Silber BM, Milos PM. PMID: 11741249; PMCID: PMC2751283.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    17. in Biomarkers and Surrogate Endpoints: Clinical Research and Applications, edited by G. Downing. The Importance of Biomarkers in Drug Discovery and Development-Focus on Alzheimer's Disease. 2000.
    18. Proceedings of the First International Pharmacogenomics and Pharmacogenetics Forum, edited by T. Noguchi and Y. Fujita. Use of Genetic Variation-Response Outcome Relationships in Drug Development and Discovery. 1999.
    19. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 1997 Oct; 283(1):46-58. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. PMID: 9336307.
      View in: PubMed   Mentions: 165     Fields:    Translation:HumansAnimals
    20. A novel quantitative method for determining the biodistribution of radiolabeled xenobiotics using whole-body cryosectioning and autoradioluminography. J Pharmacol Exp Ther. 1995 Feb; 272(2):953-62. Potchoiba MJ, Tensfeldt TG, Nocerini MR, Silber BM. PMID: 7853213.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    21. Pharmacokinetics of tiqueside (beta-tigogenin cellobioside) in dogs, rats, rabbits, and monkeys. J Pharm Sci. 1995 Jan; 84(1):12-4. Inskeep PB, Connolly AG, Cole MJ, Luther EW, Biehl ML, Marzetta CA, Savoy YE, Silber BM. PMID: 7714734.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    22. Pharmacokinetic principles in the design of immediate-release components in sustained-release formulations with zero-order release characteristics. J Pharm Sci. 1991 Feb; 80(2):142-8. Cheung WK, Silber BM, Yacobi A. PMID: 2051317.
      View in: PubMed   Mentions:    Fields:    
    23. Pharmacokinetics of YTR830H in healthy human subjects. J Chemother. 1989 Jul; 1(4 Suppl):505-6. Cheung WK, Greene DS, Kuye O, Smith MP, Holder A, Fernandez P, Houston A, Faulkner RD, Silber BM. PMID: 16312505.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    24. Pharmacokinetics of YTR830H and piperacillin after intravenous coadministration. J Chemother. 1989 Jul; 1(4 Suppl):507-8. Cheung WK, Greene DS, Kuye O, Shin K, Tonelli AP, Houston A, Hibberd M, Faulkner RD, Silber BM. PMID: 16312506.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Bioequivalency of oral suspension formulations of cefixime. Biopharm Drug Dispos. 1989 Mar-Apr; 10(2):205-11. Faulkner RD, Sia LL, Barone JS, Forbes SJ, Silber BM. PMID: 2706319.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    26. Pharmacokinetics of Nilvadipine After Multiple Dosing to Steady-State. Drug Dev. Indus. Pharm. . 1989; (15):51-63.
    27. Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine. J Clin Pharmacol. 1988 Nov; 28(11):1001-7. Cheung WK, Sia LL, Woodward DL, Graveline JF, Desjardins RE, Yacobi A, Silber BM. PMID: 3243913.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    28. Pharmacokinetic evaluation of a sustained-release formulation of trihexyphenidyl in healthy volunteers. J Pharm Sci. 1988 Sep; 77(9):748-50. Cheung WK, Stravinski SS, Engel SI, Sia LL, Yacobi A, Silber BM. PMID: 3225767.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    29. Absolute bioavailability of cefixime in man. J Clin Pharmacol. 1988 Aug; 28(8):700-6. Faulkner RD, Fernandez P, Lawrence G, Sia LL, Falkowski AJ, Weiss AI, Yacobi A, Silber BM. PMID: 3216036.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    30. Pharmacokinetics of cefixime in the young and elderly. J Antimicrob Chemother. 1988 Jun; 21(6):787-94. Faulkner RD, Bohaychuk W, Lanc RA, Haynes JD, Desjardins RE, Yacobi A, Silber BM. PMID: 3410802.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    31. In vitro protein binding interaction studies involving cefixime. Biopharm Drug Dispos. 1988 May-Jun; 9(3):315-20. Bialer M, Wu WH, Faulkner RD, Silber BM, Yacobi A. PMID: 3395672.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    32. Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog. Drug Metab Dispos. 1988 Mar-Apr; 16(2):222-7. Wu WH, Henderson BM, Lanc R, Garnes D, Yacobi A, Silber BM. PMID: 2898337.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    33. Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers. Int J Clin Pharmacol Res. 1988; 8(5):299-305. Cheung WK, Woodward DL, Shin K, Hibberd M, Pearse S, Desjardins RE, Yacobi A, Silber BM. PMID: 3229870.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    34. The pharmacokinetics of cefixime in the fasted and fed state. Eur J Clin Pharmacol. 1988; 34(5):525-8. Faulkner RD, Bohaychuk W, Haynes JD, Desjardins RE, Yacobi A, Silber BM. PMID: 3203716.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    35. Changes in tissue concentrations of 14C-doxorubicin caused by mitoxantrone, mithramycin A and vinblastine in the rat. Res Commun Chem Pathol Pharmacol. 1988 Jan; 59(1):61-8. Cheung WK, Aiache M, Yacobi A, Silber BM. PMID: 2965402.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    36. Bioequivalency of Solid Oral Dosage Forms of Cefixime. Int. J. Pharmaceut. 1988; (43):53-58.
    37. Drug Absorption from Sustained Release Formulations, Edited by A. Yacobi and E. Halperin-Walega. Utilizing Pharmacokinetic Principles in the Design of Controlled or Sustained Release Formulations. 1988; 1-33.
    38. Determination of cefixime in biological samples by reversed-phase high-performance liquid chromatography. J Chromatogr. 1987 Nov 27; 422:145-52. Falkowski AJ, Look ZM, Noguchi H, Silber BM. PMID: 3437003.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    39. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J. 1987 Oct; 6(10):963-70. Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM. PMID: 3696837.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    40. Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. J Clin Pharmacol. 1987 Oct; 27(10):807-12. Faulkner RD, Bohaychuk W, Desjardins RE, Look ZM, Haynes JD, Weiss AI, Silber BM. PMID: 3429686.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    41. Liquid-chromatographic determination of five orally active cephalosporins--cefixime, cefaclor, cefadroxil, cephalexin, and cephradine--in human serum. Clin Chem. 1987 Oct; 33(10):1788-90. McAteer JA, Hiltke MF, Silber BM, Faulkner RD. PMID: 3665031.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    42. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding. Res Commun Chem Pathol Pharmacol. 1987 Apr; 56(1):21-32. Bialer M, Wu WH, Look ZM, Silber BM, Yacobi A. PMID: 3589152.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    43. Dose-dependent pharmacokinetics of a new oral cephalosporin, cefixime, in the dog. Pharm Res. 1987 Feb; 4(1):33-7. Bialer M, Batra VK, Morrison JA, Silber BM, Look ZM, Yacobi A. PMID: 3508527.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    44. Decapeptyl: Release from Microcapsules and Testosterone Suppression in the Dog, The Pharmacology and Toxicology of Proteins, pp. 337-349. 1987.
    45. Pharmacokinetic Approach to the Rational Design of Controlled or Sustained Release Formulations. J. Control. Rel. 1987; 3(5):263-270.
    46. Sustained and Controlled Release Drug Delivery Systems, 2nd Edition, edited by J.R. Robinson and V.H. Lee. Pharmacokinetic-Pharmacodynamic Basis of Controlled Drug Delivery. 1987; 213-251.
    47. The relationship between drug input and mean residence time in the body. Biopharm Drug Dispos. 1986 Nov-Dec; 7(6):577-83. Bialer M, Look ZM, Silber BM, Yacobi A. PMID: 3828487.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    48. Nonlinear formation of propranolol metabolites in dogs after portacaval transpositions. J Pharmacokinet Biopharm. 1984 Aug; 12(4):401-12. Lo MW, Pond SM, Effeney DJ, Silber BM, Riegelman S, Tozer TN. PMID: 6527232.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    49. Pharmacokinetics: A Modern View, edited by L.Z. Benet and G. Levy. Stereoselective Disposition and Glucuronidation of Propranolol in Man. 1984; 478-481.
    50. Pharmacokinetics: A Modern View, edited by L.Z. Benet and G. Levy. The Use of the Portacaval Transposition Technique to Study Gastrointestinal and Hepatic Metabolism of Propranolol in the Dog. 1984; 474-477.
    51. Chemical aspects of propranolol metabolism. Synthesis and identification of 3-(4-hydroxy-1-naphthoxy)propane-1,2-diol as a metabolite of propranolol in the dog, in man and in the rat liver 9000g supernatant fraction. Res Commun Chem Pathol Pharmacol. 1983 Nov; 42(2):235-44. Gupte SM, Bartels MJ, Kerr BM, Laganiere S, Silber BM, Nelson WL. PMID: 6658188.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    52. Dose-dependent elimination of propranolol and its major metabolites in humans. J Pharm Sci. 1983 Jul; 72(7):725-32. Silber BM, Holford NH, Riegelman S. PMID: 6886977.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    53. Stereoselective disposition and glucuronidation of propranolol in humans. J Pharm Sci. 1982 Jun; 71(6):699-704. Silber B, Holford NH, Riegelman S. PMID: 7097538.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    54. A technique to study hepatic and intestinal drug metabolism separately in the dog. J Pharmacol Exp Ther. 1982 May; 221(2):507-11. Effeney DJ, Pond SM, Lo MW, Silber BM, Riegelman S. PMID: 7077540.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    55. Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition. J Pharmacol Exp Ther. 1982 May; 221(2):512-5. Lo MW, Effeney DJ, Pond SM, Silber BM, Riegelman S. PMID: 7077541.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    56. An automated HPLC method for the assay of propranolol and its basic metabolites in plasma and urine. J Chromatogr Sci. 1982 Mar; 20(3):126-31. Lo MW, Silber B, Riegelman S. PMID: 7076780.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    57. In vivo effects of the cytochrome P-450 suicide substrate 2-isopropyl-4-pentenamide (allylisopropylacetamide) on the disposition and metabolic pattern of propranolol. J Pharmacol Exp Ther. 1981 Oct; 219(1):125-33. Silber B, Mico BA, Ortiz de Montellano PR, Dols DM, Riegelman S. PMID: 7288600.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    58. Stereospecific assay for (-)- and (+)-propranolol in human and dog plasma. J Pharmacol Exp Ther. 1980 Dec; 215(3):643-8. Silber B, Riegelman S. PMID: 7441523.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    59. The influence of heparin administration on the plasma protein binding and disposition of propranolol. Res Commun Chem Pathol Pharmacol. 1980 Mar; 27(3):419-29. Silber B, Lo M, Riegelman S. PMID: 7384636.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    60. [Hepatic and renal toxicity of enflurane (author's transl)]. Anesth Analg (Paris). 1980; 37(7-8):427-8. Bernad PG, Silber B, Mathieu A. PMID: 7425324.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    61. Drug Level Monitoring, edited by W. Sadee and G.C.M. Beelen. Acetazolamide; Hydrochlorthiazide; Tetrahydrocannabinol. 1980; 117-119; 268-270; 447-453.
    62. Spironolactone-associated digoxin radioimmunoassay interference. Clin Chem. 1979 Jan; 25(1):48-50. Silber B, Sheiner LB, Powers JL, Winter ME, Sadée W. PMID: 761378.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    B Michael's Networks
    Concepts (189)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (13)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-868-g8ba5679c on PROFILES-PWEB02.

    Copyright © The Regents of the University of California